BW20030808002008  20030808T123132Z UTC


( BW)(IVAX-CORPORATION)(IVX) Product Launch

    Business Editors
    UK REGULATORY NEWS

    MIAMI--(BUSINESS WIRE)--Aug. 8, 2003--

               IVAX Launches Cefuroxime Axetil Tablets

IVAX Corporation (AMEX:IVX) (LSE:IVX.L) announced today that its
wholly owned subsidiary, IVAX Pharmaceuticals, Inc., is distributing
cefuroxime axetil tablets in 250 mg and 500 mg dosage strengths.
Cefuroxime axetil is the generic equivalent of Ceftin(R), which is
marketed by GlaxoSmithKline, and is an orally-administered antibiotic
used to treat patients with mild to moderate infections. The U.S.
sales of Ceftin and cefuroxime axetil tablets in 250 and 500 mg
strength were approximately $239 million for the past twelve months,
ending in March, 31, 2003.

IVAX Corporation, headquartered in Miami, Florida, discovers,
develops, manufactures, and markets branded and brand equivalent
(generic) pharmaceuticals and veterinary products in the U.S. and
internationally.

Copies of this and other news releases may be obtained free of charge
from IVAX' website at http://www.ivax.com.

   Short Name: IVAX Corporation
   Category Code: PRL
   Sequence Number: 00008204
   Time of Receipt (offset from UTC): 20030807T194151+0100

    --30--GAA/mi*  DB/ny

    CONTACT: IVAX Corporation, Miami
             David Malina, 305/575-6043

    KEYWORD: FLORIDA UNITED KINGDOM INTERNATIONAL EUROPE
    INDUSTRY KEYWORD: PHARMACEUTICAL PRODUCT
    SOURCE: IVAX Corporation

Today's News On The Net - Business Wire's full file on the Internet
                          with Hyperlinks to your home page.
                          URL: http://www.businesswire.com